The discovery of ER by Dr. Elwood Jensen exactly 60 years ago has not only led to the birth of a whole new vital nuclear receptor research field but also made a rapid, direct and lasting impact on the treatment and prevention of breast cancer. Since that landmark discovery, tremendous progress has been made in our understanding of the molecular functions of ER and development of targeted therapies against ER pathways for breast cancer treatment. However, there is currently no book available addressing these discoveries and recent advancement in a historical and systematic fashion. This book is intended to provide comprehensive, most up-to-date information on the history and recent advancement of ER and breast cancer by world renowned leaders in the field. These chapters include the history of the discovery of ER; physiological and pathological roles of ER; recent discovery of ER cistrome, transcriptome and its regulation of noncoding RNAs such as microRNAs and enhancer RNAs in breast cancer; development and clinical practices of the first targeted therapy Tamoxifen and other antiestrogens for breast cancer treatment; structural basis of ER and antiestrogen actions; molecular insights into endocrine resistance; the role of ER mutants, ER-beta and environmental estrogens in breast cancer; and emerging state-of-the-art therapeutic approaches currently in development to overcome treatment resistance and future perspectives. The book will provide undergraduate and graduate students, basic scientists and clinical cancer researchers, residents, fellows, as well as clinicians, oncology educators and the general public a thorough and authoritative review of these exciting topics.

Autorentext

Dr. Xiaoting Zhang received his B.S. in Biochemistry and Microbiology from Zhejiang University and M.S. in Genetics from Institute of Genetics, Fudan University, China. He then moved to the United States and received his Ph.D. in Molecular Biology from the University of Iowa, followed by a postdoctoral study at the Rockefeller University. Dr. Zhang's laboratory focuses on understanding the molecular mechanism of estrogen receptor-mediated gene regulation in breast cancer metastasis and therapeutic resistance, and the development of RNA nanotechnology based therapeutics for their treatment. Dr. Zhang has received many awards and grants from major federal, national and local breast cancer funding agencies including NIH/NCI, DoD, American Cancer Society and Komen for the Cure Foundation. He also serves as a regularly invited grant reviewer for all these organizations, as well as international grant organizations such as Hong Kong Research Grant Council, the Marsden Fund of Royal Society of New Zealand and American Association for Cancer Research. He is a founding council member and chair of the nomination committee of the International Society of RNA Nanotechnology and Nanomedicine, and a member of the American Association for Cancer Research, American Society for Biochemistry and Molecular Biology and The Endocrine Society.

Inhalt
Introduction: On the discovery of Estrogen Receptor
Sohaib Khan Physiological and Pathological Roles of Estrogen Receptor
Ken Korach

Estrogen Receptor Cofactors
Bert O'Malley

Estrogen Receptor Pioneer Factors and Cistrome
Myles Brown/Jason Carroll Estrogen Receptor Transcriptome
Benita S Katzenellenbogen Long Range Enhancer Regulation of ER Target Genes
Rosenfeld MG/Glass C

Estrogen Receptor Regulation of microRNAs
Ken Nephew

First Targeted Therapy --- History of Tamoxifen
Craig Jordan

Selective Estrogen Receptor Modulators (SERMs)
McDonnell DP

Anti-estrogen Therapies in Clinical Practices
Carols Arteaga

Structural Insights into ER and Anti-Estrogen Therapies
Geoff Greene

Molecular Mechanisms of Endocrine Resistance
CK Osborne

Estrogen Receptor Mutants in Breast Cancer &nbs...